Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosuke Hashimoto

Showing results (81-90 of 133) with videos related to

Pageof 14
Sort By:
Anticancer Research|March 27, 2024
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung CancerKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Thoracic Cancer|February 28, 2019
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patientsAyako Shiono, Kyoichi Kaira, Atsuto Mouri, et al.
Thoracic Cancer|April 8, 2022
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancerHisao Imai, Erika Naito, Ou Yamaguchi, et al.
Acta Histochemica Et Cytochemica|May 20, 2021
Raman Spectroscopic Assessment of Myocardial Viability in Langendorff-Perfused Ischemic Rat HeartsKoki Ikemoto, Kosuke Hashimoto, Yoshinori Harada, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutationsAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|August 22, 2023
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinibKyoichi Kaira, Hisao Imai, Atsuto Mouri, et al.
Scientific Reports|October 10, 2025
Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapyNaohito Hashimoto, Shota Takei, Kyoichi Kaira, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation MarkersYu Miura, Hisao Imai, Satoshi Endo, et al.
Journal of Thoracic Disease|April 16, 2026
Prognostic value as metabolic tumor activity on <sup>18</sup>F-FDG uptake in thymic epithelial tumorsKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Thoracic Cancer|February 24, 2021
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancerHisao Imai, Ou Yamaguchi, Keita Mori, et al.
Pageof 14

Showing results (81-90 of 133) with videos related to

Sort By:
Pageof 14
Anticancer Research|March 27, 2024
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung CancerKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Thoracic Cancer|February 28, 2019
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patientsAyako Shiono, Kyoichi Kaira, Atsuto Mouri, et al.
Thoracic Cancer|April 8, 2022
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancerHisao Imai, Erika Naito, Ou Yamaguchi, et al.
Acta Histochemica Et Cytochemica|May 20, 2021
Raman Spectroscopic Assessment of Myocardial Viability in Langendorff-Perfused Ischemic Rat HeartsKoki Ikemoto, Kosuke Hashimoto, Yoshinori Harada, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutationsAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|August 22, 2023
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinibKyoichi Kaira, Hisao Imai, Atsuto Mouri, et al.
Scientific Reports|October 10, 2025
Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapyNaohito Hashimoto, Shota Takei, Kyoichi Kaira, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation MarkersYu Miura, Hisao Imai, Satoshi Endo, et al.
Journal of Thoracic Disease|April 16, 2026
Prognostic value as metabolic tumor activity on <sup>18</sup>F-FDG uptake in thymic epithelial tumorsKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Thoracic Cancer|February 24, 2021
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancerHisao Imai, Ou Yamaguchi, Keita Mori, et al.
Pageof 14